FRENKEL TOPPING GROUP PLC (FEN) — Investment Research Note

Executive summary

Frenkel Topping is a UK specialist financial and professional services group serving personal-injury and clinical-negligence (PI/CN) claimants, combining an IFA business and discretionary fund manager (Ascencia, £1.63bn FUM) with costs-law, expert-witness, accountancy, case-management and major-trauma-signposting subsidiaries. Across the period covered, revenue compounded strongly (£10.2m FY20 → £37.4m FY24, +17% to £20.9m in H1 25) driven by a roll-up strategy, with FUM growing from ~£1.0bn to >£1.6bn while adjusted EBITDA expanded from £2.5m to £8.0m, although organic margins have been pressured by Consumer Duty fee resets, NI/NMW cost inflation and County Court delays. The single most important point for valuation today is that on 30 September 2025 the Independent Directors unanimously recommended a Harwood Private Equity cash offer at 50p plus a contingent value right (CVR) worth up to 10p — the listed share price (50p) effectively is the offer price, so the stock is functionally a takeover/CVR arbitrage, not a public-market investment thesis 2025-09-30 Recommended Offer; market data 2026-06-12.

Fair value estimate

• Fair value range: 50p – 60p per share (£61m – £74m market cap)
• Methodology: Anchored on the recommended Harwood cash offer (50p fixed, deemed fair and reasonable by Cavendish/Independent Directors), plus an expected-value adjustment for the CVR (zero to 10p, payable only if a future PE exit clears a 100p hurdle on Irwell Holdco ordinary shares after PIK note repayment and preference share redemption). The fundamental case as a standalone listed entity is broadly consistent with this: 50p offer = ~8.0x FY24 adjusted EBITDA / ~13x adjusted EPS of 3.9p, which is in line with UK small-cap wealth/IFA M&A precedents.
• Comparison to current £61.4m mcap: The market is fully discounting the cash element. Upside to the high end (60p) is +20%, downside to the floor (50p) is 0%.
• Note on offer status: Documented deal timetable indicated scheme effectiveness in late 2025; however market data shows the shares still quoted at 50p in mid-2026 with 122.9m shares outstanding. Either the scheme completed and the line is technical/stub, or the deal has elongated. Either way, the price discovery cap is the offer.

Sector context

• Sector classification confirmed: ICB Financial Services (specialist diversified financial services / wealth management).
• Quality/growth/leverage vs. peers: Quality is above typical AIM small-cap peers (99% retention, recurring DFM fees, ~21% adj. EBITDA margin), growth is in line with consolidator peers, leverage is modestly above the sector with £3.8m net debt growing from net cash in 2022 due to deferred-consideration payments and recent RCF drawdowns 2024-04-28 FY24 results.
• Listed peers: Mattioli Woods (delisted by PE — direct comparable for both business and exit mechanism), Brooks Macdonald, Brewin/RBC (large-cap), Kingswood Holdings; none are pure-play PI/CN.

Investment thesis (3 bullets)

1. Defined cash exit at 50p underwritten by a recommended PE bid. Independent Directors unanimously recommend the cash leg; NASCIT (29.96%) + IPGL + Onward + Downing irrevocables/letter of intent = 36.7% of voting scheme shares plus NASCIT bound — high probability of completion 2025-09-30 Recommended Offer.
2. Free optionality on the CVR (up to 10p extra) on Harwood's 4–7 year exit. Harwood explicitly intends to add bolt-ons, drive AI in reporting, and target margin/scale uplift; if the exit values the Holdco ordinary shares above 100p, holders of the cash offer share proportionately in upside per penny over the hurdle 2025-09-30 Recommended Offer Appendix II.
3. Underlying business is genuinely high-quality recurring-revenue compounder. £1.63bn FUM (+12% H1 25), 99% retention, 84% of new H1 25 mandates flowing into higher-fee equity solutions vs. 43% prior year, Ascencia Defaqto Defensive Comparator winner — supports the floor valuation and the chance of CVR payment 2025-09-30 Interim Results.

Key risks (3 bullets)

1. CVR is structurally subordinated and likely worth little. Hurdle = 100p per Irwell Holdco Ordinary Share after repayment of PIK loan notes accruing at 20% p.a. and redemption of preference shares; Strand Hanson have not been required to confirm CVR-funding resources, and the payment "could be zero" 2025-09-30 Recommended Offer Appendix II. Treat CVR as a low single-digit pence call option, not a guaranteed top-up.
2. Cost-base headwinds and County Court delays compress organic earnings. Adjusted EBITDA margin compressed from 24.4% (FY23) to 21.4% (FY24); £360k FY25 / £500k annualised hit from NI/NMW; debtor days in Costs segment 385 (FY24) due to SCCO and County Court backlogs — the underlying entity would face slower organic growth without PE support 2024-04-28 FY24 results; 2025-02-03 Trading Update.
3. Concentrated/related-party deal structure. Chairman Christopher Mills controls Harwood Capital and is CEO/IM of NASCIT (29.96% holder and concert party with bidder) — i.e. the largest shareholder is on the bid side. This caps competing-bid optionality (no realistic interloper) and means market price gravity = 50p, not fundamental value 2025-09-30 Recommended Offer §1.

Operating leverage

The Group has moderate operating leverage. Cost base is dominated by direct staff costs (£23m on £37.4m FY24 revenue = 62%); these are largely variable to revenue (fee earners in costs-law, IFAs, expert witnesses). Central admin is ~£6.4m and is the genuinely fixed slice — so on the existing scale, an incremental £4m revenue beat (10%) at sector-typical 40–50% contribution margin would add roughly £1.6–£2.0m to adjusted EBITDA, i.e. take EBITDA from £8m to £9.6–10.0m (+20–25%). The high-leverage point is Ascencia DFM: incremental FUM at higher-fee equity solutions earns near-software margin since infrastructure is already built — the H1 25 swing of 84% of new mandates into higher-fee solutions vs. 43% prior year is precisely the kind of mix effect that drops disproportionately to profit. That said, this is not a fixed-cost software/platform model — it is mostly people-based professional services, so the user's "long-tail multiples of profit" outcome is constrained. The takeover thesis explicitly cites cost saves from delisting (£0.5–1m annual public-company cost) plus AI-in-reporting efficiency — both real but modest 2024-04-28 FY24; 2025-09-30 Interim Results; 2025-09-30 Recommended Offer §4.

Value-trap signals

• Three-year share price decline of 43.8% (77p → 43p) pre-bid despite revenue more than doubling — symptom of small-cap AIM illiquidity and persistent guidance challenges around Ascencia FUM growth, Consumer Duty fee changes and Costs-segment delays 2025-09-30 Recommended Offer §5.
• Repeated downgrades over 2023–24 referenced explicitly by Independent Directors: "Company having to downgrade expectations" 2025-09-30 Recommended Offer §5.
• Material related-party governance overhang: Chairman is the controlling shareholder of the bidder vehicle's manager — historically a depressing factor on the public-market multiple.
• Working capital lengthening in Costs segment (debtor days up to 385 days, FY24 vs 309 FY23) — structural, not cyclical 2024-04-28 FY24.

Earnings vs. expectations

The pattern across 2023–2025 is in line to mildly disappointing on the underlying business, with confidence guarded by management language ("in line with management expectations") rather than beats. FY22 trading update (Feb 2023) flagged revenue in line but Adjusted EBITDA ~8% below management's prior expectation due to PIC underperformance and Consumer Duty fee changes; FY23 results delivered EBITDA of £8.0m, flat vs FY22 despite revenue growth (consensus had been somewhat higher); H1 24 was described as "in line with revised management expectations"; FY24 and H1 25 came in "in line with management expectations." Net: more misses-or-resets than clean beats, but no profit warnings of consequence in the most recent two reporting periods.

Conviction

Conviction: 4 (high). The fair-value call is anchored by an explicit, recommended, advised-as-fair cash offer of 50p, irrevocably supported by ~37% of voting scheme shares plus a concert-party 30% holder bound to elect for the alternative — this is about as unambiguous a valuation anchor as a small-cap can offer.

• Anchoring it: (i) Cavendish Rule 3 fairness opinion on cash leg, (ii) 30% concert-party already bound, (iii) listing currency price = offer price = independent-director consensus.
• Limiting it: (i) CVR valuation is genuinely uncertain and I have to assume it's near-worthless given the PIK note seniority; (ii) the post-2025 status of the scheme isn't visible from filings alone (the offer was due to close late 2025 but shares are still quoted in mid-2026 at the offer level, raising small process-status uncertainty).

Headline assessment for the investor profile

For a portfolio targeting AI receivers + operating leverage + valuation discipline, FEN is a poor fit: it is a small UK PI/CN financial-services consolidator with effectively zero AI exposure, modest operating leverage, and a share price already pinned to a PE take-out. The capital is being returned at a defined price — that is good risk control but it offers virtually no participation in the AI cycle and very limited operating-leverage convexity. The CVR is the only "long-tail" element and is structurally subordinated.